Application
of Chinese Herbal Medicine in COVID-19 Open Access
Yehong Tian, Xiaowei Qiu, Xin Jiang,
Jinchang Huang, Fengyu Zhang
April
12, 2021
DOI:10.36316/gcatr.03.0041
ABSTRACT
Traditional Chinese herbal medicine has
a long history in treating febrile diseases, according to the Shang Han Lun,
a classical theory of traditional Chinese medicine developed by Zhang Zhongjing
in the Han Dynasty. Some herbs have been formulated as prescription formulae or
manufactured as finished medicine such as pills, capsules or injections. The
Chinese government has recommended specific TCM prescriptions alone or combined
with Western medicine to treat patients with COVID-9. Here,
we introduce three prescription formulae, Qingfei Paidu Decoction, Huashi
Baidu Formula, and Xuanfei Baidu Formula, three finished
medicines, Lianhua Qingwen Capsule, Jinhua Qinggan Granule,
and Xuebijing Injection; following this, several single herbs such as Ephedra
herba, Honeysuckle, Scutellaria, Glycyrrhizae radix, Armeniacae
semen, Sophorae flavescentis radix, and Curcuma longa. We
review existing evidence of these traditional medicines and herbs for their
related antiviral activities, efficacy, and underlying mode of action in
virus-related diseases. Most of these drugs have been traditionally used in
Chinese medicine for over a thousand years, and they have been proved to be
safe in treating flu-like virus infections. It will be adequate to further test
for their efficacy for COVID-19 and understand the underlying molecular
mechanism.
KEYWORDS
COVID-19, SARS-CoV-2,
Traditional Chinese medicine, herbal medicine
Copyright©
2021 by the author(s).
Licensee Global Clinical and
Translational Research. This is an open-access article distributed under the
terms and conditions of the Creative Commons Attribution License (CCBY4.0,
https://creative-commons.org/ licenses /by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium provided the original work is
properly cited.
How to cite this article:
Tian Y, Qiu X, Jiang X, Huang J, Zhang F.
Application of Chinese herbal medicine in COVID-19. Glob Clin Transl Res. 2021;
3(2): 21-35. DOI:10.36316/gcatr.03.0041
REFERENCES
1.
Chan K, Wong V, Tang S. COVID-19: An Update on the
Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines
of Integrative Chinese-Western Medicine for the Management of 2019 Novel
Coronavirus Disease. The American journal of Chinese medicine.
2020;48(3):737-62. https://doi.org/10.1142/S0192415X20500378.
2.
Ren J, Zhang A, Wang X. Traditional Chinese
medicine for COVID-19 treatment. Pharmacological research. 2020;155:104743.https://doi.org/10.1016/j.phrs.2020.104743.
3.
Yang Y, Islam M, Wang J, et al. Traditional Chinese
Medicine in the Treatment of Patients Infected with 2019-New Coronavirus
(SARS-CoV-2): A Review and Perspective. Int J Biol Sci. 2020;16(10):1708-17；https://doi.org/10.7150/ijbs.45538.
4.
Wang W, Wang Y, Ma S, et al. [Analysis of
strategy, participation rate and cure effect of traditional Chinese medicine in
treating COVID-19 in 23 Provinces ( Municipalities and Autonomous Regions)].
World Chinese Medicine. 2020;15(6):6-13.
5.
Zhou L, Wang J, Xie R, et al. The Effects of
Traditional Chinese Medicine as an Auxiliary Treatment for COVID-19: A
Systematic Review and Meta-analysis. J Altern Complement Med.
2021;27(3):225-37.https://doi.org/10.1089/acm.2020.0310.
6.
National Health Commission & State
Administration of Traditional Chinese Medicine. Diagnosis and Treatment
Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl).
2020;133(9):1087-95. https://doi.org/10.97/CM9.0000000000000819.
7.
Bao Y, Shi Y, Guo S, et al. [Therapeutic effect of
Compound Qinlan Oral Liquid on treating combining disease with syndrome of
human coronavirus pneumonia with pestilence attacking lung syndrome]. Zhongguo
Zhong Yao Za Zhi. 2020;45(7):1473-80. https://doi.org/10.19540/j.cnki.cjcmm.20200303.402.
8.
Guo S, Li D, Shi Y, et al. [Efficacy evaluation of
Jinchai Kangbingdu capsule based on coronaryvirus pneumonia with 'Hanshi Yidu
Xifei' syndrome model]. Chinese Journal of Experimental Traditional Medical
Formulae. 2020;26(13):1-7. https://doi.org/10.13422/j.cnki.syfjx.20201401.
9.
Bao L, Shi Y, Geng Z, et al. [Application of
Reyanning Mixture in evaluating combining disease with syndrome of human
coronavirus pneumonia with pestilence attacking lung syndrome]. Zhongguo Zhong
Yao Za Zhi. 2020;45(7):1465-72. https://doi.org/10.19540/j.cnki.cjcmm.20200303.401.
10.
State Administration of Traditional Chinese
Medicine. TCM on COVID-19 treatment.
http://wwwsatcmgovcn/xinxifabu/meitibaodao/2020-04-01/14418html. 2020.
11.
Liang S, Zhang Y, Shen C, et al. Chinese herbal
medicine used with or without conventional western therapy for COVID-19: An
evidence review of clinical studies. Front Pharmacol. 2020;11:583450. https://doi.org/10.3389/fphar.2020.
12.
Zhang F, Walters M. Pathogen genomics and host
cellular susceptability factors of COVID-19. Glob Clin Transl Res.
2020;2(4):107-26. https://doi.org/10.36316/gcatr.02.0037.
13.
Hsieh C, Lo C, Liu C, et al. Mechanism by which
ma-xing-shi-gan-tang inhibits the entry of influenza virus. Journal of
ethnopharmacology. 2012;143(1):57-67. https://doi.org/10.1016/j.jep.2012.05.061.
14.
Lin C, Wang Y, Chen S, et al. Shegan-Mahuang
Decoction ameliorates asthmatic airway hyper-responsiveness by downregulating
Th2/Th17 cells but upregulating CD4+FoxP3+ Tregs. J Ethno-pharmacol.
2020;253:112656. https://doi.org/10.1016/j.jep.2020.
15.
Zheng N, Dai J, Cao H, et al. Current
understanding on antihepatocarcinoma effects of xiao chai hu tang and its
constituents. Evidence-Based Complementary and Alternative Medicine.
2013;2013(529458). https://doi.org/10.1155/2013/529458.
16.
Yang Y, Zhang D, Liu J, et al. Wuling San protects
kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3
inflammasome activation in high fructose-induced hyperuricemic mice. J
Ethnopharmacol. 2015;169:49-59. https://doi.org/10.1016/j.jep.2015.04.011.
17.
National Health Commission & State Administration
of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel
Coronavirus Pneumonia (Trial Version 8). 2020:p.1-25. https://doi.org/10.1097/CM9.0000000000000819.
18. Xin S, Cheng X,
Zhu B, et al. Clinical retrospective study on the efficacy of Qingfei Paidu
decoction combined with Western medicine for COVID-19 treatment. Biomed
Pharmacother. 2020;129:110500. https//doi.org/10.1016/j.biopha.2020.110500.
19.
Wang E, Tang L, Xu K, et al. [Efficacy evaluation
of Qingfeipaidu Decoction in the treatment of 75 cases of mild and common type
of OVID-19 with enzymatic index]. Pharmacy and Clinics of Chinese Materia
Medica. 2020;11(1):3-5.
20.
Wang R, Yang S, Xie C, et al. [Clinical efficacy
of Qingfeipaidu Decoction in the treatment of COVID-19]. Pharmacology and
Clinical Practice of Traditional Chinese Medicine. 2020;36(1):13-8. https://doi.org/0.13412/j.cnki.zyyl.20200303.002.
21. Chen J, Wang Y,
Gao Y, et al. Protection against COVID-19 injury by qingfei paidu decoction via
antiviral, anti-inflammatory activity and metabolic program-ming. Biomed
Pharmacother. 2020;129: 110281.https://doi.org/10.1016/j.biopha.2020.110281.
22.
Hopkins AL. Network pharmacology. Nat Biotechnol.
2007;25(10):1110-1. https://doi.org/10.038/nbt007-.
23.
Hillen H, Kokic G, Farnung L, et al. Structure of
replicating SARS-CoV-2 polymerase. Nature. 2020;584(7819):154-6. https://doi.org/10.1038/s41586-020-2368-8.
24.
Peng X, Yang X, Xu G, et al. [Investigating
Clinical Efficacy and Mechanism of Qingfei Paidu Decoction for Treatment of
COVID-19 Based on Integrative Pharmacology]. Zhongguo Shiyan Fangji Xue Zazhi
[Chinese Journal of Experimental Traditional Medical Formulae].
2020;26(6):6-13. https://doi.org/0.13422/j.cnki.syfjx.20201638.
25.
Xu D, Xu Y, Wang Z,et al. [Research on the
mechanism of Qingfei Paidu Decoction in the treatment of COVID-19 based on
network pharmacology]. Zhongyao Yaoli Yu Linchuang [Pharmacology and Clinics of
Chinese Materia Medica]. 2020;36(1):26-32. https://doi.org/10.13412/j.cnki.zyyl.20200305.001.
26.
Zhao J, Tian S, Yang J, et al. [Investigating
mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network
pharmacology]. Zhong Cao Yao [Chinese Traditional and Herbal Drugs].
2020;51(4):829-35. http://www.tiprpress.com/zcy/article/abstract/20200401?st=article_issue.
27.
Wu H, Wang J, Yang Y, et al. [Preliminary
exploration of the mechanism of Qingfei Paidu decoction against novel
coronavirus pneumonia based on network pharmacology and molecular docking
technology]. Acta Pharmaceutica Sinica. 2020;55(3):374-83. https://doi.org/10.16438/j.0513-4870.2020-0136.
28.
Yang R, Liu H, Bai C, et al. Chemical composition
and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan
Decoction against Coronavirus Disease 2019 (COVID-19): In silico and
experimental study. Pharmacological Research. 2020;157:104820. https://doi.org/10.1016/j.phrs.2020.
29.
Liu W, Ge G, Wang Y, et al. [Chemical constituent
and tissue distribution study of Qingfei Paidu Decoction in mice using
UHPLC-Q-Orbitrap HRMS]. Chinese Traditional and Herbal Drugs. 2020;51(8). https://doi.org/10.7501/j.issn.0253-2670.2020.
08.007.
30.
Zou B, Li M, Fan T, et al. [Experience summary and
the diagnosis and treatment program of TCM on severe COVID-19]. J Tradit Chin
Med. 2020;61(15):1289-93. https://doi.org/10.13288/j.11-2166/r.2020.15.001.
31.
Zhao Y, Hou X, Gao Z, et al. [Research on
Medication for Severe Type of COVID-19 Based on Huashi Baidu Prescription]. Chinese
archives of traditional medicine. 2020;38(6):14-7. https://doi.org/0.13193/j.issn.1673-7717.2020.06.
004.
32.
Shi N, Guo L, Liu B, et al. Efficacy and safety of
Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with
coronavirus disease 2019: A non-randomized controlled trial. Phytomedicine.
2021;81:153367. https://doi.org/10.1016/j.phymed.2020.
33.
Huang L. Efficacy and Safety Assessment of Severe
COVID-19 Patients with Chinese Medicine: a Retrospective Case Series Study at
Early Stage of the COVID-19 Epidemic in Wuhan, China. J Ethno-pharmacol.
2021:113888. https//doi.org/10.1016/j.jep.2021.113888.
34.
Min J, Kim D, Jin Y, et al. Kurarinone Inhibits
HCoV-OC43 Infection by Impairing the Virus-Induced Autophagic Flux in MRC-5
Human Lung Cells. Journal of clinical medicine. 2020;9(7):2230. https://doi.org/10.3390/jcm9072230.
35.
Tao Q, Du J, Li X, et al. Network pharmacology and
molecular docking analysis on molecular targets and mechanisms of Huashi Baidu
formula in the treatment of COVID-19. Drug Dev Ind Pharm. 2020;46(8):1345-53. https://doi.org/10.080/03639045.2020.1788070.
36.
Zhu Y, Yan X, Ye T, et al. Analyzing the potential
therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through
integrating network pharmacological methods. J Tradit Complement Med.
2021;11(2):180-7. https://doi.org/10.1016/j.jtcme.2021.01.004.
37.
Lai Q, Liang A, He M, et al. [Pharmacological
mechanism and network pharmacology research of Huashibaidu formula in treating
COVID-19]. Nat Prod Res Dev. 2020;32:909-19. https://doi.org/10.16333/j.1001-6880.2020.6.002.
38.
Xiong W, Wang G, Du J, et al. Efficacy of herbal
medicine (Xuanfei Baidu decoction) combined with conventional drug in treating
COVID-19:A pilot randomized clinical trial. Integr Med Res. 2020;9(3):100489. https://doi.org/10.1016/j.imr.2020..
39.
Wang Y, Li X, Zhang J, et al. Mechanism of Xuanfei
Baidu Tang in treatment of COVID-19 based on network pharmacology. China
journal of Chinese materia medica. 2020;45(10):2249-56. https://doi.org/10.19540/j.cnki.cjcmm.20200325.401.
40.
Wang H, Song H, Wang D, et al. [Potential
mechanism of Xuanfei Baidu Formula in treating new coronavirus pneumonia based
on network pharmacology and molecular docking]. Journal of Hainan Medical
University. 2020;26(18):1-8. https://doi.org/10.13210/j.cnki.jhmu.20200617.003.
41.
Ding Y, Zeng L, Li R, et al. The Chinese
prescription lianhuaqingwen capsule exerts anti-influenza activity through the
inhibition of viral propagation and impacts immune function. BMC Complementary
and Alternative Medicine. 2017;17(1):130. https://doi.org/10.1186/s12906-017-1585-7.
42.
Zhong N, Li Y, Yang Z, et al. Chinese guidelines
for diagnosis and treatment of influenza (2011). J Thorac Dis.
2011;3(4):274-89. https://doi.org/10.3978/j.issn.2072-1439.2011.
10.01.
43.
Ding X. [Pharmacological analysis of Lianhua
Qingwen against influenza virus]. Linchuang Heli Yongyao Zazhi [Journal of
Clinical Rational Drug Use]. 2012;5(28):32. https://doi.org/10.15887/j.cnki.13-1389/r.2012.28.
017.
44.
Cheng D, Li Y. [Clinical Effectiveness and Case
Analysis in 54 NCP Patients Treated with Lanhuaqingwen Granules]. World Chinese
Medicine. 15(2):150–4. https://doi.org/10.3969/j.issn.1673-7202.2020.
02.006.
45.
Fang J, Li H, Du W, et al. Efficacy of Early Combination
Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19
Patients: A Retrospective Cohort Study. Front Pharmacol. 2020;11(560209). https://doi.org/10.3389/fphar.2020.560209.
46.
Yao K, Liu M, Li X, et al. [Retrospective clinical
analysis on treatment of novel coronavirus infected pneumonia with traditional
chinese medicine Lianhua Qingwen]. Chin J Exp Trad Med. 2020;26(11):8-12. https://doi.org/0.13422/j.cnki.syfjx.20201099.
47.
Hu K, Guan W, Bi Y, et al. Efficacy and safety of
Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with
coronavirus disease 2019: A multicenter, prospective, randomized controlled
trial. Phytomedicine. 2020:153242. https://doi.org/10.1016/j.phymed.2020.
48.
Zhu S, Li X, Wei Y, et al. [Inhibitory effects of three
prescriptions of traditional Chinese medicine on SARS-associated
coronavirus in vitro]. Letters in
biotechnology. 2003;14(5):390-2.
49.
Li R, Hou Y, Huang J, et al. Lianhuaqingwen exerts
antiviral and anti-inflammatory activity against novel coronavirus
(SARS-CoV-2). Pharmacological research. 2020;156(10476). https://doi.org/10.1016/j.phrs.2020.104761.
50.
Chen X, Wu Y, Chen C, et al. Identifying potential
anti-COVID-19 pharmacological components of traditional Chinese medicine
Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography
screening. Acta pharmaceutica Sinica B. 2021;11(1):222-36. https://doi.org/10.1016/j.apsb.2020.10.002.
51.
Liu Z, Li X, Gou C, et al. [Effect of Jinhua
Qinggan granules on novel coronavirus pneumonia in patients]. J Tradit Chin
Med. 2020;40(3):467-72. https://doi.org/10.19852/j.cnki.jtcm.2020.03.016.
52.
Duan C, Xia W, Zheng C, et al. [Clinical
Observation on Jinhua Qinggan Granule Combined with Conventional Western
Medicine Therapy in Treating Mild Cases of Coronavirus Disease 2019]. J
Traditional Chinese Medicine. 2020;61(78):1473-7. https://doi.org/10.13288/j.11-2166/r.2020.17.001.
53.
Shi H, Hong Y, Qian J, et al. Xuebijing in the
treatment of patients with sepsis. Am J Emerg Med. 2017;35(2):285-91. https://doi.org/10.1016/j.ajem.2016.11.007.
54.
Luo Z, Chen W, Xiang M, et al. The preventive
effect of Xuebijing injection against cytokine storm for severe patients with
COVID-19: A prospective randomized controlled trial. Eur J Integr Med.
2021;42:101305. https://doi.org/10.1016/j.eujim.2021.
55.
Guo H, Zheng J, Huang G, et al. Xuebijing
injection in the treatment of COVID-19: a retrospective case-control study. Ann
Palliat Med. 2020;9(5):3235-48. https://doi.org/10.21037/apm-20-1478.
56.
Kong Y, Lin L, Chen Y, et al. [Mechanism of
XueBiJing Injection on Treatment of Coronavirus Disease 2019 Based on Network
Pharmacology]. Modernization of Traditional Chinese Medicine and Materia Materia-World
Science and Technology 2020;22(3):552-60.
57.
Zheng W, Yan Q, Ni Y, et al. Examining the
effector mechanisms of Xuebijing injection on COVID-19 based on network
pharmacology. BioData Min. 2020;13:17. https://doi.org/0.1186/s13040-020-00227-6.
58.
Zhuo X, Chen J, Tian M, et al. [Research Progress
on Chemical Constituents and Pharmacological Effects of Ephedra sinica].
Information on Traditional Chinese Medicine. 2020;38(2):80-3. https://doi.org/10.19656/j.cnki.1002-2406.210216.
59.
Sun X, Li H, Liu T, et al. [Research Progress on Chemical
Constituents and Clinical Application of Ephedra Plants]. Chinese
Pharmaceutical Affairs. 2020;32(2):201-9. https://doi.org/10.16153/j.1002-7777.2018.02.008.
60.
Wei W, Du H, Shao C, et al. Screening of Antiviral
Components of Ma Huang Tang and Investigation on the Ephedra Alkaloids Efficacy
on Influenza Virus Type A. Frontiers in Pharmacology. 2019;10(10):961. https://doi.org/10.3389/fphar.2019.00961.
61.
Gao K, Song Y, Song A. Exploring active
ingredients and function mechanisms of Ephedra-bitter almond for prevention and
treatment of Corona virus disease 2019 (COVID-19) based on network
pharmacology. BioData Min. 2020;13(1):19. https://doi.org/0.1186/s13040-020-00229-4.
62.
Yu Y. [Analysis on the active components and
pharmacological effects of honeysuckle]. Inner Mongolia journal of traditional
Chinese medicine. 2017;36(14):131-50. https://doi.org/10.16040/j.cnki.cn15-1101.2017.
14.130.
63.
Hu K, Wang Y, Sun K. [Experimental Study on the
Induction of α - interferon of Human Ieucocyte in Vitro by Chlorogenic Acid from
the Honeysuckle]. Information on Traditional Chinese Medicine.
2010;27(4):105-7.
64. Wang G, Shi L,
Ren Y, et al. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid
and caffeic acid in vivo and in vitro. Antiviral research. 2009;83(2):186-90. https://doi.org/10.1016/j.antiviral.2009.05.002.
65.
Ding Y, Cao Z, Cao L, et al. Antiviral activity of
chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of
neuraminidase. Sci Rep 2017;7:45723. https://doi.org/10.1038/srep.
66.
Wang H, Chi Q, Xiong S, et al. [Effects of
Lonicera japonica extract on lung inflammation in LPS-induced ARDS rats].
Journal of Guangdong Pharmaceutical University. 2017;33(3):379-82. https://doi.org/10.16809/j.cnki.2096-3653.
2016121402.
67.
Lou X, Hu J, Wang F, et al. [Effect of honeysuckle
on expression of Caspase-3 and NF-κB in mice with viral myocarditis]. Shanghai
Zhong Yi Za Zhi [Shanghai Journal of Traditional Chinese Medicine].
2019;53(9):71-4. https://doi.org/10.16305/j.1007-1334.2019.09.019.
68.
Zhang X, Zheng M, Zhu Z, et al. [Studies on the
anti-respiratory syncytial virus effect of honeysuckle in vitro]. New Chinese
medicine. 2014;46(6):204-6. https://doi.org/10.13457/j.cnki.jncm.2014.06.097.
69.
Jia W, Mao S, Zhang P, et al. [Study on Antiviral
Effect of Lonicera Japonica Thumb Polysaccharide in Vivo]. J Liaoning Univ Trad
Chinese Med. 2018;20(6):25-7. https://doi.org/10.13194/j.issn.1673-842x.
2018.06.007.
70.
Guo X, Wang X, Su W, et al. DNA barcodes for
discriminating the medicinal plant Scutellaria baicalensis (Lamiaceae) and its
adulterants. Biol Pharm Bull. 2011;34(8):1198-203. https://doi.org/10.248/bpb.34.
71.
Zheng Y, Wang J, Fu C, et al. [Research progress
on chemical constituents and pharmacological effects of Scutellaria baicalensis
Georgi]. Chinese Traditional Patent Medicine. 2016;38(1):141-7.
72.
Rao Z, Ma M, Lou Z, et al. [Method for screening
SARS coronavirus main protease inhibitor from traditional Chinese medicine].
China patent. 2010; CN200910235347. 2010 2009-10-21.
73.
Wu Y, Jin Y, Wu J, et al. [Antiviral effects of
major constituents of Huangqin (RadixScutellariae) on influenza A virus (FM1)
in vitro]. Journal of Beijing University of Traditional Chinese Medicine. 2010;
33(8):541-5.
74.
Xu H, Li Y, Wang C, et al. [Effect of Scutellariae
Ｒadix on expression of inflammatory cytokine
protein and gene in lung of mice with viral pneumonia caused by influenza virus
FM1 infection]. China Journal of Chinese Materia Medica. 2019;44(23):5166-73. https://doi.org/10.19540/j.cnki.cjcmm.201910.09.401.
75.
Li Y, Gao H, Zhu Q, et al. [Research Progress on
antiviral activity of chemical constituents from Glycyrrhiza uralensis Fisch].
Shandong Journal of Traditional Chinese Medicine. 2020;36(2):167-71. https://doi.org/10.16295/j.cnki.0257-358x.2017.
02.025.
76.
Luo H, Tang Q, Shang Y, et al. Can Chinese
medicine be used for prevention of coronavirus disease 2019 (COVID-19)? A
review of historical classics, research evidence and current prevention
programs. Chinese journal of integrative medicine. 2020;26(4):243-50. https://doi.org/10.1007/s11655-020-3192-6.
77.
Zhou P, Yang X, Wang X, et al. A pneumonia
outbreak associated with a new coronavirus of probable bat origin. Nature.
2020;579(7798):270-3. https://doi.org/10.1038/s41586-020-2012-7.
78.
Murck H. Symptomatic Protective Action of
Glycyrrhizin (Licorice) in COVID-19 Infection? Front Immunol. 2020;11:1239. https://doi.org/10.3389/fimmu.2020.01239.
79.
Chen F, Chan K, Jiang Y, et al. In vitro
susceptibility of 10 clinical isolates of SARS coronavirus to selected
antiviral compounds. J Clin Virol. 2004;31(1):69-75. https://doi.org/10.1016/j.jcv.2004.03.003.
80.
Wang X, Hao H, Chu L. Glycyrrhizin inhibits
LPS-induced inflammatory mediator production in endometrial epithelial cells.
Microb Pathog. 2017; 109:110-3. https://doi.oeg/10.1016/j.micpath.2017.05.032.
81.
Seo E, Song G, Kwak B, et al. Effects of
Glycyrrhizin on the Differentiation of Myeloid Cells of the Heart and Lungs in
Lipopolysaccharide-Induced Septic Mice. Shock. 2017;48(3):371-6. https://doi.org/10.1097/SHK.0000000000000850.
82.
Li J, Ma X, Shen J, et al. Screening of active
components from Chinese materia medica against SARS-CoV-2 based on literature
mining and molecular docking. Zhong Cao Yao [Chinese Traditional and Herbal
Drugs]. 2020;51(5).
83.
Li K, Shi Q, Zhu H, et al. [Chemical Compositions
in Bitter Almond]. Journal of Northwest Forestry University. 2004;19(2):124-6.
84.
Yang G, WL, Wang D, et al. [Pharmacological
research progress of bitter almond]. Zhong Shou Ti Xue Za Zhi [Chinese Journal
of Veterinary Medicine]. 2017;197(4):75-6.
85. Li Y, Chu F, Li
P, et al. Potential effect of Maxing Shigan decoction against coronavirus
disease 2019 (COVID-19) revealed by network pharmacology and experimental
verification. J Ethnopharmacol. 2021;271:113854. https://doi.org/10.1016/j.jep.2021.113854.
86.
Zhao X, Sun N, Bai X, et al. [Inhibitory action
and mechanism of matrine against porcine reproductive and respiratory syndrome
virus in vitro]. Zhong Shou Yi Xue Za Zhi [Chinese Journal of Veterinary
Medicine]. 2013;33(6):808-12. https://doi.org/10.16303/j.cnki.1005-4545.2013.
06.012.
87.
Chen J, Shen H, Niu M, et al. Anti-hepatitis B virus
effect of matrine-type alkaloid and involvement of p38 mitogen-activated
protein kinase and tumor necrosis factor receptor-associated factor 6. Virus
research. 2015; (215)104-13. https://doi.org/10.1016/j.virusres.2015.12.005.
88.
Sun J, Guo S, Shi Y, et al. [Effect of matrine
sodium chloride injection on a mouse model combining disease with syndrome of
human coronavirus pneumonia with cold-dampness pestilence attacking the lung].
Acta Pharmaceutica Sinica. 2020;55:366-73. https://doi.org/10.16438/j.0513-4870.2020-0222.
89.
Yang M, Ceng F, Zhu D, et al. [Clinical efficacy
of Matrine and Sodium Chloride Injection in treatment of 40 cases of COVID-19].
China Journal of Chinese Materia Medica. 2020;45(10):2221-31. https://doi.org/10.19540/j.cnki.cjcmm.20200323.501.
90.
Nishikawa S, Inoue Y, Hori Y, et al.
Anti-Inflammatory Activity of Kurarinone Involves Induction of HO-1 via the
KEAP1/Nrf2 Pathway. Antioxidants (Basel). 2020;9(9):842. https://doi.org/10.3390/antiox9090842.
91.
Moghadamtousi S, Kadir H, Hassandarvish P, et al.
A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin.
BioMed Research International. 2014:186864. https://doi.org/10.1155/2014/.
92.
Praditya D, Kirchhoff L, Brüning J, et al.
Anti-infective Properties of the Golden Spice Curcumin. Frontiers in
Microbiology. 2019;10:912. https://doi.org/10.3389/fmicb.2019.00912.
93.
Hesari A, Ghasemi F, Salarinia R, et al. Effects
of curcumin on NF-κB, AP-1, and Wnt/β-catenin signaling pathway in hepatitis B
virus infection. Journal of Cellular Biochemistry. 2018; 119(10): 7898-904. https://doi.org/10.1002/jcb.26829.
94.
Moradi M, Karimi A, Rafieian-Kopaei M, et al. In vitro
antiviral effects of Peganum harmala seed extract and its total alkaloids
against Influenza virus. Microb Pathog. 2017;110:42-9. https://doi.org/10.1016/j.micpath.2017.06.014.
95. Mounce BC, Cesaro
T, Carrau L, Vallet T, Vignuzzi M. Curcumin inhibits Zika and chikungunya virus
infection by inhibiting cell binding. Antiviral research. 2017;142:148-57. https://doi.org/10.1016/j.antiviral.2017.03.014.
96.
Li Y, Wang J, Liu Y, et al. Antiviral and
virucidal effects of curcumin on transmissible gastroenteritis virus in vitro.
The Journal of general virology. 2020;101 (10): 1079-84. https://doi.org/10.1099/jgv.0.001466.